- Home
- JBLU vs ZLAB Comparison
JBLU vs ZLAB Comparison
Compare JBLU & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- ZLAB
- Stock Information
- Founded
- JBLU 1998
- ZLAB 2013
- Country
- JBLU United States
- ZLAB China
- Employees
- JBLU N/A
- ZLAB N/A
- Industry
- JBLU Air Freight/Delivery Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- ZLAB Health Care
- Exchange
- JBLU Nasdaq
- ZLAB Nasdaq
- Market Cap
- JBLU 1.9B
- ZLAB 3.6B
- IPO Year
- JBLU N/A
- ZLAB 2017
- Fundamental
- Price
- JBLU $4.47
- ZLAB $35.49
- Analyst Decision
- JBLU Sell
- ZLAB Buy
- Analyst Count
- JBLU 11
- ZLAB 5
- Target Price
- JBLU $4.97
- ZLAB $54.28
- AVG Volume (30 Days)
- JBLU 21.4M
- ZLAB 938.1K
- Earning Date
- JBLU 07-29-2025
- ZLAB 08-05-2025
- Dividend Yield
- JBLU N/A
- ZLAB N/A
- EPS Growth
- JBLU N/A
- ZLAB N/A
- EPS
- JBLU N/A
- ZLAB N/A
- Revenue
- JBLU $9,210,000,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- JBLU N/A
- ZLAB $44.07
- Revenue Next Year
- JBLU $7.75
- ZLAB $49.13
- P/E Ratio
- JBLU N/A
- ZLAB N/A
- Revenue Growth
- JBLU N/A
- ZLAB 43.72
- 52 Week Low
- JBLU $3.34
- ZLAB $16.01
- 52 Week High
- JBLU $8.31
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- JBLU 48.61
- ZLAB 49.61
- Support Level
- JBLU $4.11
- ZLAB $34.55
- Resistance Level
- JBLU $4.39
- ZLAB $36.73
- Average True Range (ATR)
- JBLU 0.22
- ZLAB 1.31
- MACD
- JBLU 0.00
- ZLAB -0.56
- Stochastic Oscillator
- JBLU 61.17
- ZLAB 10.59
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.